Immodulon is developing heat-killed whole cell mycobacterial products as systemic immune-modulators for the treatment of cancer and other conditions where dysfunction of the immune system may contribute to disease aetiology and progression.
Our lead product, IMM‑101 (Mycobacterium obuense National Collection of Type Cultures [NCTC] 13365), is a naturally derived medical treatment that helps the body’s immune system to recognise and control cancer. IMM-101 works in combination with other anti-cancer treatments to improve the overall outcome for patients with various forms of cancer.
Immodulon Therapeutics Ltd, 6-9 The Square, Uxbridge, United Kingdom UB11 1FW.
Tel: 0203 137 6346 website: www.Immodulon.com